Pentosan polysulfate to control hepcidin expression in vitro and in vivo.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
05 2020
Historique:
received: 11 12 2019
accepted: 18 02 2020
pubmed: 24 2 2020
medline: 30 10 2020
entrez: 24 2 2020
Statut: ppublish

Résumé

Hepcidin peptide is crucial in the regulation of systemic iron availability controlling its uptake from the diet and its release from the body storage tissues. Hepcidin dysregulation causes different human disorders ranging from iron overload (e.g. hemochromatosis) to iron deficiency (e.g. anemia). Hepcidin excess is common in the Anemia of Chronic Diseases or Anemia of Inflammation and in the genetic form of anemia named IRIDA; the pharmacological downregulation of hepcidin in these disorders could improve the anemia. Commercial heparins were shown to be strong inhibitors of hepcidin expression, by interfering with BMP6/SMAD pathway. The non-anti-coagulant heparins, modified to abolish the anti-thrombin binding site, were equally potent and could be used to improve iron status. To perform its anti-hepcidin activity heparin needs 2O- and 6O-sulfation and an average molecular weight (MW) up to 4000-8000 Dalton, depending on the sulfation level. The pentosane polysulfate (PPS), which shares with heparin a high degree of sulfation, is a compound with low anti-coagulant activity that is already in use for pharmaceutical treatment. In the present work we analyzed the anti-hepcidin activity of PPS in vitro and in vivo. We found that it acts as a strong inhibitor of hepcidin expression in HepG2 cells with an effect already visible after 2-3 h of treatment. It also suppressed hepcidin in mice in a dose dependent manner after 3 h and with a significant redistribution of systemic iron without evident side effects. PPS is also able to abolish the LPS dependent hepcidin upregulation similarly to that showed for heparin derivatives. These results suggest PPS as an interesting compound to control hepcidin in vivo.

Identifiants

pubmed: 32088260
pii: S0006-2952(20)30095-2
doi: 10.1016/j.bcp.2020.113867
pii:
doi:

Substances chimiques

Hepcidins 0
Pentosan Sulfuric Polyester 37300-21-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113867

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Michela Asperti (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Andrea Denardo (A)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Magdalena Gryzik (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Annalisa Castagna (A)

Department of Medicine, University of Verona, Verona, Italy.

Domenico Girelli (D)

Department of Medicine, University of Verona, Verona, Italy.

Annamaria Naggi (A)

G. Ronzoni Institute for Chemical and Biochemical Research, Milano, Italy.

Paolo Arosio (P)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Maura Poli (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. Electronic address: maura.poli@unibs.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH